These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 18025258

  • 1. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.
    Zhou Z, Reddy K, Guan H, Kleinerman ES.
    Mol Cancer Res; 2007 Nov; 5(11):1125-32. PubMed ID: 18025258
    [Abstract] [Full Text] [Related]

  • 2. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
    Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, Hicklin DJ, Kleinerman ES.
    Clin Cancer Res; 2007 Aug 15; 13(16):4867-73. PubMed ID: 17699866
    [Abstract] [Full Text] [Related]

  • 3. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
    Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES.
    Clin Cancer Res; 2005 Apr 01; 11(7):2662-9. PubMed ID: 15814647
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma.
    Jia SF, Duan X, Worth LL, Guan H, Kleinerman ES.
    Cancer Gene Ther; 2006 Oct 01; 13(10):948-57. PubMed ID: 16763609
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas.
    Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES.
    Cancer Res; 2010 Feb 15; 70(4):1334-43. PubMed ID: 20124484
    [Abstract] [Full Text] [Related]

  • 10. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration.
    Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K, Chou AJ, Koshkina NV, Kleinerman ES.
    Cancer; 2007 Oct 01; 110(7):1568-77. PubMed ID: 17694551
    [Abstract] [Full Text] [Related]

  • 11. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor.
    Reddy K, Zhou Z, Jia SF, Lee TH, Morales-Arias J, Cao Y, Kleinerman ES.
    Int J Cancer; 2008 Aug 15; 123(4):831-7. PubMed ID: 18537159
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature.
    Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES.
    Angiogenesis; 2008 Aug 15; 11(3):257-67. PubMed ID: 18344025
    [Abstract] [Full Text] [Related]

  • 14. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature.
    Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES.
    Int J Cancer; 2006 Aug 15; 119(4):839-46. PubMed ID: 16557578
    [Abstract] [Full Text] [Related]

  • 15. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
    Wang J, Shi YQ, Yi J, Ye S, Wang LM, Xu YP, He M, Kong XM.
    J Dig Dis; 2008 Nov 15; 9(4):228-37. PubMed ID: 18959596
    [Abstract] [Full Text] [Related]

  • 16. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, Scotlandi K.
    Clin Cancer Res; 2007 Feb 15; 13(4):1322-30. PubMed ID: 17317844
    [Abstract] [Full Text] [Related]

  • 17. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes.
    Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA.
    Cancer Res; 2006 Sep 15; 66(18):9054-64. PubMed ID: 16982747
    [Abstract] [Full Text] [Related]

  • 18. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo.
    Raskopf E, Vogt A, Sauerbruch T, Schmitz V.
    J Hepatol; 2008 Dec 15; 49(6):977-84. PubMed ID: 18845354
    [Abstract] [Full Text] [Related]

  • 19. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.
    Chernoguz A, Crawford K, Donovan E, Vandersall A, Berglund C, Cripe TP, Frischer JS.
    J Surg Res; 2012 Mar 15; 173(1):1-9. PubMed ID: 21658718
    [Abstract] [Full Text] [Related]

  • 20. Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice.
    He XW, Yu X, Liu T, Yu SY, Chen DJ.
    Chin Med J (Engl); 2008 Mar 05; 121(5):439-44. PubMed ID: 18364118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.